New Milford, CT, United States of America

Lifen Wu

USPTO Granted Patents = 23 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 15 (Patent Applications = 8)

Average Co-Inventor Count = 8.7

ph-index = 7

Forward Citations = 159(Granted Patents)

Company Filing History:

19 out of 1,535

Boehringer Ingelheim International Gmbh

patents

4 out of 276

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

Years Active: 2006-2022

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11358967 - Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma (2022-06-14),

2. 10954215 - Compounds as modulators of ROR gamma (2021-03-23),

3. 9598415 - Compounds as modulators of RORγ (2017-03-21),

4. 9242989 - Compounds as modulators of RORγ (2016-01-26),

5. 9174980 - Heterocyclic compounds as inhibitors of leukotriene production (2015-11-03),

6. 8889670 - Heterocyclic compounds which modulate the CB2 receptor (2014-11-18),

7. 8735430 - Compounds which selectively modulate the CB2 receptor (2014-05-27),

8. 8658661 - Oxadiazole inhibitors of leukotriene production (2014-02-25),

9. 8629157 - Pyrrolidine compounds which modulate the CB2 receptor (2014-01-14),

10. 8580829 - Oxadiazole inhibitors of leukotriene production (2013-11-12),

11. 8580825 - Oxadiazole inhibitors of leukotriene production (2013-11-12),

12. 8575201 - Oxadiazole inhibitors of leukotriene production (2013-11-05),

13. 8420655 - Benzimidazole inhibitors of leukotriene production (2013-04-16),

14. 8383615 - Azetidine 2-carboxamide derivatives which modulate the CB2 receptor (2013-02-26),

15. 8372874 - Compounds which selectively modulate the CB2 receptor (2013-02-12),

Title: The Innovative Works of Inventor Lifen Wu in Modulating ROR Gamma

Introduction:

Inventor Lifen Wu, based in New Milford, CT (US), has made significant contributions to the field of pharmaceuticals with his groundbreaking discoveries. With an impressive portfolio of 23 patents, Wu is recognized for his work in developing compounds that serve as modulators of ROR gamma, offering promising avenues for the treatment of associated diseases.

Latest Patents:

Wu's latest patents revolve around the development of substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma. These compounds, as outlined in the formula (I), demonstrate efficacy in modulating ROR gamma and show potential in treating diseases linked to this modulation. Additionally, the invention includes processes for synthesizing these compounds and the formulation of pharmaceutical preparations containing them.

Career Highlights:

Throughout his career, Wu has been associated with esteemed companies such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. His tenure in these organizations has been marked by a relentless pursuit of innovation and a steadfast commitment to advancing the frontiers of pharmaceutical research and development.

Collaborations:

A testament to Wu's collaborative spirit, he has worked alongside accomplished individuals in the field, including Doris Riether and Renee M Zindell. Together, they have synergized their expertise to drive forward novel approaches in ROR gamma modulation, fostering a culture of innovation and excellence in their endeavors.

Conclusion:

In conclusion, Lifen Wu stands as a pioneering figure in the realm of pharmaceutical inventions, with a remarkable track record of patents that have the potential to transform the landscape of ROR gamma modulation and disease treatment. His collaborative efforts and unwavering dedication underscore his status as a trailblazer in the field, inspiring future generations of inventors and researchers to push the boundaries of innovation even further.

This text is generated by artificial intelligence and may not be accurate.